Literature DB >> 2189593

Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide.

J A Green1, K Smith.   

Abstract

In two separate studies of patients with ovarian cancer, subjects were treated on a protocol comprising 400 mg/m2 carboplatin in combination with 1 g/m2 cyclophosphamide (group A) or 5 g/m2 ifosfamide with mesna (group B). The dose intensities achieved in group A were 87.2 mg/m2 carboplatin per week and 245.8 mg/m2 cyclophosphamide per week (34 patients). In group B, the dose intensities achieved were 124.1 mg/m2 carboplatin per week and 2,020 mg/m2 ifosfamide per week (25 patients). Two formulae for the prediction of the optimal dose of carboplatin based on renal function and degree of myelosuppression are compared with that based on surface area, and that recently proposed by Calvert is recommended. The importance of dose intensity and the total dose delivered in phase II and III studies is emphasized.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189593     DOI: 10.1007/bf00685411

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Time-dose factors in chemotherapy: expanding the concept of dose-intensity.

Authors:  A J Dembo
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

Review 2.  The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors:  W Hryniuk; H Bush
Journal:  J Clin Oncol       Date:  1984-11       Impact factor: 44.544

3.  Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.

Authors:  V H Bramwell; H T Mouridsen; A Santoro; G Blackledge; R Somers; J Verwey; P Dombernowsky; M Onsrud; D Thomas; R Sylvester
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

4.  Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

Authors:  M J Egorin; D A Van Echo; E A Olman; M Y Whitacre; A Forrest; J Aisner
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

5.  Optimal prescription method for cancer chemotherapy.

Authors:  H M Vriesendorp
Journal:  Exp Hematol       Date:  1985       Impact factor: 3.084

6.  Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.

Authors:  L Levin; W M Hryniuk
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

7.  Phase I studies with carboplatin at the Royal Marsden Hospital.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

8.  Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.

Authors:  D Alberts; N Mason; E Surwit; S Weiner; N Hammond; G Deppe
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

9.  Results of NCI-sponsored phase I trials with carboplatin.

Authors:  B J Foster; K Clagett-Carr; B Leyland-Jones; D Hoth
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

  9 in total
  5 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  The use of the Calvert formula to determine the optimal carboplatin dosage.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

4.  Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.

Authors:  Y Ando; H Minami; H Saka; M Ando; S Sakai; K Shimokata
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.